Bimagrumab
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Phase 2 · Withdrawn · Enrollment 0
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.